Physician

Terry R Jenkins, M.D.

According to 2025 Medicare claims, Terry Jenkins, M.D. (NPI: 1063467298) practices hematology/oncology in the College Station-Bryan, TX market, with the plurality of this provider's patient population coming from Brazos, TX. This provider's primary affiliated billing organization is BRAZOS VALLEY HEMATOLOGY ONCOLOGY ASSOCIATES, PA (NPI: 1376594432; TIN: 742803009) and primary practice location at 77802-2585. Jenkins is affiliated with the Baylor Scott & White Quality Alliance (ACO ID: A2542), participating under the MSSP model.

Jenkins' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 415 traditional Medicare patients, billed 110,013 HCPCS/CPT codes, and received $1,589,461 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 830 prescription claims across 121 beneficiaries totaling $3,493,324 in drug costs, led by Imbruvica (Ibrutinib). 2023 DME data shows 11 claims. Open Payments data shows 43 records totaling $1,245. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $1,814,064 to $1,589,461. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $655,015 to $3,493,324. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	419	126,970	$1,814,064
2016	424	199,240	$2,693,288
2017	501	200,159	$2,975,311
2018	463	173,880	$2,848,827
2019	373	134,159	$2,259,467
2020	311	84,812	$1,753,142
2021	268	93,077	$1,557,992
2022	265	114,633	$1,909,107
2023	300	95,235	$1,714,496
2024	415	110,013	$1,589,461

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	159	1,004	$655,015
2016	163	973	$1,032,713
2017	163	1,168	$1,481,602
2018	170	1,192	$1,853,608
2019	159	1,137	$2,591,820
2020	134	932	$2,141,699
2021	129	910	$2,897,353
2022	125	859	$2,859,852
2023	104	723	$2,925,475
2024	121	830	$3,493,324

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	73	$8,277
2016	N/R	78	$13,308
2017	N/R	26	$6,660
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	30	$3,364
2021	N/R	12	$1,413
2022	N/R	38	$1,747
2023	N/R	11	$614
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	81	235	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	128	223	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	89	125	$65
36415	Insertion of needle into vein for collection of blood sample	250	610	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	203	542	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	42	1,176	$673,858
Calquence	Acalabrutinib Maleate	33	990	$478,375
Revlimid	Lenalidomide	27	756	$475,939
Xtandi	Enzalutamide	30	900	$379,665
Ibrance	Palbociclib	16	448	$254,438

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	43	$1,245	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Terry R. Jenkins, M.D.?

Tedicare shows public-source Medicare data for Terry R. Jenkins, M.D. (NPI 1063467298), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Terry R. Jenkins, M.D. have ACO affiliation data?

Terry R. Jenkins, M.D. is shown with ACO affiliation data for Baylor Scott & White Quality Alliance (MSSP, ACO ID A2542).

What billing organization is linked to Terry R. Jenkins, M.D.?

Terry R. Jenkins, M.D. is linked to BRAZOS VALLEY HEMATOLOGY ONCOLOGY ASSOCIATES, PA (billing NPI 1376594432) in the available physician profile data.

Does Terry R. Jenkins, M.D. have Open Payments data?

Terry R. Jenkins, M.D. has 43 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.